US FDA warning Illegally marketed stem cell therapy made in substandard lab

US FDA warning: Illegally marketed stem cell therapy made in substandard lab

06:48 EST 14 Nov 2018 | BioPharma-Reporter

California-based StemGenex marketed its SVF drug without an approved biologics license application, according to the agency.

More From BioPortfolio on "US FDA warning: Illegally marketed stem cell therapy made in substandard lab"